Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for…
On Childhood Cancer Day, SHEPHERD Therapeutics is joining forces with Oncoheroes Biosciences to bring new treatment options to children and adolescents with cancer. SHEPHERD is a Boston-based biotech company on a mission to change the way rare cancer is treated,…
An additional venture philanthropy organization, the Catalytic Impact Foundation, which supports women’s health, brain health, children’s health, aging, and pediatric rare disease initiatives, is investing in AIM-HI Accelerator Fund portfolio company Oncoheroes Biosciences, further validating the start-up’s unique effort to…
Tvardi Therapeutics, an AIM-HI Accelerator Fund portfolio company, has won recognition as one of the ten “Most Promising” companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is…
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare…
Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its…
Oncoheroes Biosciences, currently working on the clinical development of volasertib, a potential new drug for rhabdomyosarcoma patients, is honored to announce the receipt of funding from Super Sam Foundation, a pediatric cancer non-profit. Read more: https://oncoheroes.com/insights-news-1/2020/5/29/oncoheroes-biosciences-and-super-sam-foundation-walking-together-for-the-pediatric-cancer-heroes
Oncoheroes Biosciences, a biotech focused exclusively on advancing new therapies for children with cancer, receives another endorsement from a childhood cancer non-profit. The support received by The Gregory Foundation for Cancer Research will help accelerate the clinical drug development of…
Three Decades of NFCR Basic and Translational Research Funding to Primary Investigator Dr. Yung-Chi Cheng and Project Advances New Systems Biology Paradigm for Cancer Treatment World-First Phase II Multi-Regional Clinical Trial for a Botanical Cancer Drug Candidate ROCKVILLE, MD –…
ROCKVILLE, MD & BOSTON, MA – An AIM-HI Accelerator Fund portfolio company exclusively focused on the development of pediatric cancer therapeutics has garnered recognition and additional funding. Oncoheroes Biosciences Inc. won the Squinto-LePera Award at the Lyfebulb-Helsinn Cancer Innovation Summit…
